Last week the FDA approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets. The new drugs are not approved for patients with type 1 diabetes.
Alogliptin is a new active ingredient, while metformin hydrochloride and pioglitazone are already FDA-approved for the management of type 2 diabetes. Alogliptin helps stimulate the release of insulin after eating, which leads to better blood sugar control.
People with type 2 diabetes are either resistant to insulin or do not produce enough insulin, resulting in high blood sugar levels. Over time, high blood sugar levels can increase the risk for serious complications, including heart disease, blindness, and nerve and kidney damage. About 24 million people suffer from type 2 diabetes, accounting for more than 90% of diabetes cases diagnosed in the U.S.
[1] FDA News Release, "FDA approves three new drug treatments for type 2 diabetes" (Jan. 25, 2013).
Alogliptin is a new active ingredient, while metformin hydrochloride and pioglitazone are already FDA-approved for the management of type 2 diabetes. Alogliptin helps stimulate the release of insulin after eating, which leads to better blood sugar control.
People with type 2 diabetes are either resistant to insulin or do not produce enough insulin, resulting in high blood sugar levels. Over time, high blood sugar levels can increase the risk for serious complications, including heart disease, blindness, and nerve and kidney damage. About 24 million people suffer from type 2 diabetes, accounting for more than 90% of diabetes cases diagnosed in the U.S.
[1] FDA News Release, "FDA approves three new drug treatments for type 2 diabetes" (Jan. 25, 2013).
RSS Feed
